INNOVIVA, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
INNOVIVA, INC. (INVA) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $1.23 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.23B.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.34B.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.17B.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.01B.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $1.23B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.34B 10-Q · filed 2026-08-05 |
| 2025-12-31 | $1.17B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.01B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $714.82M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $646.90M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $691.16M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $668.54M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $665.51M 10-Q · filed 2025-11-05 |
| 2024-03-31 | $703.68M 10-Q · filed 2025-11-05 |
| 2023-12-31 | $674.96M 10-K · filed 2026-02-25 |
| 2023-09-30 | $627.49M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $555.09M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $561.49M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $565.79M 10-K · filed 2026-02-25 |
| 2022-09-30 | $641.37M 10-Q · filed 2023-11-01 |
| 2022-06-30 | $565.46M 10-Q · filed 2023-11-01 |
| 2022-03-31 | $552.22M 10-Q · filed 2023-11-01 |
| 2021-12-31 | $525.93M 10-K · filed 2025-02-26 |
| 2021-09-30 | $491.81M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $393.75M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $696.68M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $607.84M 10-K/A · filed 2024-03-05 |
| 2020-09-30 | $534.87M 10-Q · filed 2021-10-27 |
| 2020-06-30 | $492.81M 10-Q · filed 2021-10-27 |
| 2020-03-31 | $405.87M 10-Q · filed 2021-10-27 |
| 2019-12-31 | $342.12M 10-K · filed 2023-02-28 |
| 2019-09-30 | $283.76M 10-Q · filed 2020-10-28 |
| 2019-06-30 | $246.70M 10-Q · filed 2020-10-28 |
| 2019-03-31 | $199.94M 10-Q · filed 2020-10-28 |
| 2018-12-31 | $159.05M 10-K/A · filed 2022-03-17 |
| 2018-09-30 | -$108.28M 10-Q · filed 2019-10-30 |
| 2018-06-30 | -$155.36M 10-Q · filed 2019-10-30 |
| 2018-03-31 | -$212.75M 10-Q · filed 2019-10-30 |
| 2017-12-31 | -$242.71M 10-K · filed 2021-02-25 |
| 2016-12-31 | -$352.99M 10-K · filed 2020-02-19 |
| 2015-12-31 | -$342.64M 10-K · filed 2019-02-19 |
| 2014-12-31 | -$223.35M 10-K · filed 2018-02-23 |
| 2011-06-30 | -$37.48M 10-Q · filed 2011-08-03 |
| 2010-12-31 | -$22.42M 10-Q · filed 2011-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |